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Introduction: Limited information exists on the etiology, prevalence, and significance of hyperdynamic left
ventricular ejection fraction (HDLVEF) in the intensive care unit (ICU). Our aim in the present study was to compare
characteristics and outcomes of patients with HDLVEF with those of patients with normal left ventricular ejection
fraction in the ICU using a large, public, deidentified critical care database.
Methods: We conducted a longitudinal, single-center, retrospective cohort study of adult patients who underwent
echocardiography during a medical or surgical ICU admission at the Beth Israel Deaconess Medical Center using
the Multiparameter Intelligent Monitoring in Intensive Care II database. The final cohort had 2867 patients, of whom
324 had HDLVEF, defined as an ejection fraction >70 %. Patients with an ejection fraction <55 % were excluded.
Results: Compared with critically ill patients with normal left ventricular ejection fraction, the finding of HDLVEF in
critically ill patients was associated with female sex, increased age, and the diagnoses of hypertension and cancer.
Patients with HDLVEF had increased 28-day mortality compared with those with normal ejection fraction in
multivariate logistic regression analysis adjusted for age, sex, Sequential Organ Failure Assessment score, Elixhauser
score for comorbidities, vasopressor use, and mechanical ventilation use (odds ratio 1.38, 95 % confidence interval
1.039–1.842, p =0.02).
Conclusions: The presence of HDLVEF portended increased 28-day mortality, and may be helpful as a gravity
marker for prognosis in patients admitted to the ICU. Further research is warranted to gain a better understanding
of how these patients respond to common interventions in the ICU and to determine if pharmacologic modulation
of HDLVEF improves outcomes.Introduction
Hyperdynamic left ventricular ejection fraction (HDLVEF)
on transthoracic echocardiography (TTE) is a frequent
finding in the intensive care unit (ICU). The American
College of Cardiology (ACC) defines HDLVEF as a left
ventricular ejection fraction >70 % [1]. In spite of the
growing use of TTE in the critical care setting, limited in-
formation exists on the etiology, prevalence, and signifi-
cance of HDLVEF in the ICU.
Prior studies have suggested increased prevalence of
HDLVEF in certain patient populations and disease pro-
cesses. Patients with sepsis commonly have low systemic* Correspondence: jrpaonessa@gmail.com
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cholamines, leading to increased contractility [3], which
could explain why patients with sepsis may develop
HDLVEF. One study demonstrated that, in patients with
septic shock, HDLVEF was more common in the subset
of patients with concurrent cirrhosis [4]. Research has
also suggested that HDLVEF in patients with non-
traumatic shock is highly specific, but not sensitive, for
sepsis [5]. Outside the diagnosis of sepsis, critically ill
patients with HDLVEF have not been studied.
In the outpatient setting, female sex and obesity have
been associated with a higher prevalence of HDLVEF
without any clear mechanism [6, 7]. Furthermore,
HDLVEF has not been shown to be associated with aer-
obic fitness [8], which suggests that HDLVEF may be due
to a pathophysiologic response rather than to cardio-
vascular conditioning. These studies have providedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Table 1 Characteristics of patients with NLVEF compared with
HDLVEF
NLVEF HDLVEF p Value
Age, yr 65 [51–78] 69 [56–78] 0.03
Male sex 1246 (49 %) 134 (41 %) <0.01
MICU 1720 (68 %) 221 (68 %) 0.9
SICU 823 (32 %) 103 (32 %) 0.9
Time to echo (days) 1.1 [0.1–3.3] 0.9 [0.0–4.2] 0.4
Time to vasopressor use (days) 0.1 [0.0–0.5] 0.1 [0.0–0.7] 1.0
Comorbidities
Diabetes mellitus 590 (23 %) 89 (27 %) 0.1
Alcohol abuse 153 (6 %) 19 (6 %) 1.0
Arrhythmias 700 (28 %) 82 (25 %) 0.4
Valvular disease 255 (10 %) 38 (12 %) 0.3
Hypertension 852 (34 %) 134 (41 %) <0.01
Renal failure 213 (8 %) 29 (9 %) 0.7
Chronic pulmonary 536 (21 %) 68 (21 %) 1.0
Liver disease 199 (8 %) 32 (10 %) 0.2
Cancer 120 (5 %) 28 (9 %) <0.01
Psychosis 117 (5 %) 15 (5 %) 1.0
Depression 148 (6 %) 12 (4 %) 0.1
CHF 841 (33 %) 127 (39 %) 0.03
CHF congestive heart failure, HDLVEF hyperdynamic left ventricular ejection
fraction on echocardiogram, MICU medical intensive care unit, NLVEF normal
left ventricular ejection fraction on echocardiogram, SICU surgical intensive
care unit
Characteristics of patients with NLVEF compared with HDLVEF are displayed as
either n (%) or median [IQR]. p Values <0.01 are listed in bold
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undefined.
There have not been any studies in which researchers
compared outcomes of patients with HDLVEF with
those of patients with normal left ventricular ejection
fraction on an electrocardiogram (NLVEF). Using a
large, public, deidentified critical care database, we stud-
ied the prevalence, characteristics, and outcomes of pa-
tients with HDLVEF in an ICU setting.
Materials and methods
We conducted a longitudinal, single-center, retrospect-
ive cohort study of adult patients who underwent TTE
during an ICU admission at the Beth Israel Deaconess
Medical Center. Data were extracted from the Multipa-
rameter Intelligent Monitoring in Intensive Care II
database (MIMIC II). MIMIC II is freely available in
the public domain and contains information derived
from the electronic medical records of 32,425 patients
admitted to the ICUs at the Beth Israel Deaconess
Medical Center between 2001 and 2008. Twenty-eight–
day mortality information was obtained from Social Se-
curity Death Index records. The creation and use of the
MIMIC II database for research was approved by the
institutional review boards of both Beth Israel Deacon-
ess Medical Center and the Massachusetts Institute of
Technology (Institutional Review Board protocol 2001-
P-001699/3). No further patient consent is required for
use of this deidentified public database.
All adult patients in the database were screened. Data
regarding age, sex, Sequential Organ Failure Assess-
ment score (SOFA) [9], laboratory values, vital signs,
diagnosis-related group (DRG) codes, and International
Classification of Diseases–Ninth Revision (ICD-9) diag-
noses were extracted. Medical comorbidities were rep-
resented by the Elixhauser score [10] for 30 comorbidities
as calculated using the DRG and ICD-9 codes from the re-
spective hospital admission. The worst values of common
pertinent laboratory results were also extracted, including
white blood cell count, lactate, and creatinine. Patients
with sepsis were identified using the Angus criteria [11].
For patients with multiple ICU stays, the first ICU ad-
mission was used. Patients in the database were admit-
ted to one of the following: medical ICU (MICU),
surgical ICU (SICU), cardiac ICU, or cardiac surgical re-
suscitation unit. The study was limited to MICU and
SICU patients to exclude elective admissions. Patients
with at least one TTE were included in the cohort.
HDLVEF was defined as an ejection fraction (EF) >70 %
based on the ACC guidelines, and NLVEF was defined
as an EF of 55–70 % [1]. Those with an EF <55 % were
excluded from the analysis to minimize confounding of
the relationship between HDLVEF and clinical out-
comes. EF was determined predominately by visualestimation using two-dimensional imaging with incorp-
oration of fractional shortening in the parasternal long-
axis view according to guidelines established by the
American Society of Echocardiography [12]. Contrast
echocardiography was used when standard imaging was
not diagnostic, and this method has been shown to reli-
ably correlate with quantitative measurements [13]. To
ensure the quality of using natural language processing
for EF categorization, a random sample of 100 TTE re-
ports was manually reviewed. This showed exceptionally
high algorithm accuracy.
Baseline comparisons were performed using Fisher’s
exact test for categorical variables, where counts and
percentages were reported. Continuous variables were
compared using a two-sample Wilcoxon rank-sum test,
also known as the Mann–Whitney U test, and reported
as median with interquartile range (IQR). Statistical sig-
nificance was defined as p values <0.01 for the baseline
characteristics shown in Table 1.
A multivariable logistic regression analysis was per-
formed with 28-day mortality as the outcome. Covariates
included age, sex, SOFA score, Elixhauser score of co-
morbidities, mechanical ventilation use, vasopressor use,
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was represented as a binary variable. Since vasopressors
have wide ranges of therapeutic intensity, sensitivity ana-
lyses were performed in the way vasopressor use was ad-
justed for. The analyses were adjusted for vasopressor
use as a binary variable (yes or no), maximum number
of vasopressors, or maximum vasopressor dose, defined
as a fraction of the highest recommended dose for each
vasopressor. The odds ratios (ORs) are preserved in the
logistic regression model with 95 % confidence intervals
(CIs). Two-sided p values <0.05 were considered statisti-
cally significant.
Results
Inclusion and exclusion criteria
As shown in Fig. 1, there were a total of 7253 patients
with TTE. The study was limited to MICU and SICU pa-
tients to exclude elective admissions. The remaining co-
hort comprised 3851 patients with TTE. Per TTE
reports, EF could not be estimated in 100 patients,
owing to poor windows, body habitus or patientFig. 1 Flow diagram showing initial selection of cohort and excluded
patients. CSRU cardiac surgical resuscitation unit, HDLVEF hyperdynamic
left ventricular ejection fraction on echocardiogram, LVEF left
ventricular ejection fraction, MICU medical intensive care unit, SICU
surgical intensive care unit, TTE transthoracic echocardiographypositioning. These patients were likewise excluded. Ul-
timately, 884 patients with depressed EF were removed.
The final cohort comprised 2867 patients, of whom 324
had HDLVEF. The time to TTE was similar between the
HDLVEF and NLVEF groups, with the median being ap-
proximately 1 day after arrival to ICU (Table 1).
Study outcome analysis
The distribution of MICU and SICU patients were simi-
lar in the groups with NLVEF and HDLVEF (Table 1).
With respect to baseline characteristics, patients with
HDLVEF were more likely to be older and female. Diag-
noses associated with HDLVEF included hypertension
and cancer, based on ICD-9 codes. There was a trend to-
ward association with congestive heart failure (CHF) and
sepsis, but it did not reach a p value <0.01. HDLVEF pa-
tients as a cohort also had a slightly higher SOFA score
(7 [IQR 4–10] vs. 6 [IQR 3–9], p <0.01), suggesting in-
creased acute disease severity. Tachycardia, lower mean
arterial pressure, leukocytosis, and higher serum lactates
were all more commonly seen in the HDLVEF cohort.
HDLVEF patients were treated more frequently with va-
sopressors and mechanical ventilation, as shown in
Table 2. Norepinephrine, phenylephrine, and dopamine
were the most frequently used vasopressors in both
groups, respectively. Dobutamine and epinephrine were
rarely used in both groups, and levosimendan was not
used in any of the patients (data not shown). Use of ino-
tropes is much more common in the cardiac and cardio-
thoracic ICU patients, who were not included in this
study.
In multivariate analysis, HDLVEF patients had in-
creased 28-day mortality compared with patients with
NLVEF (OR 1.38, 95 % CI 1.039–1.842, p =0.02) after
adjusting for age, sex, SOFA score, Elixhauser score,
mechanical ventilation, and vasopressor use (Table 3).
All three methods of representation of vasopressor use
in the sensitivity analysis did not alter the OR of the
presence of HDLVEF in the multivariable logistic regres-
sion model (data not shown).
Discussion
HDLVEF was present in 8.6 % of ICU patients who had
a TTE during their ICU admission. The median time to
TTE after arrival to the ICU was similar between groups
(Table 1), which suggests that the presence of HDLVEF
and its association with the outcome were not con-
founded by the timing of TTE.
The finding of HDLVEF was associated with female
sex, increased age, and diagnoses of hypertension and
cancer. There was a trend toward association with CHF
and sepsis. In multivariate logistic regression analysis,
patients with HDLVEF had increased 28-day mortality
compared with those with NLVEF.
Table 2 Acute illness severity and treatments performed of patients with NLVEF compared with HDLVEF
NLVEF HDLVEF p value
Acute illness indicators
SOFA score 6 [3–9] 7 [4–10] <0.01
Sepsis 1025 (40 %) 150 (46 %) 0.04
Heart rate maximum, beats/min 113 [98–130] 120 [103–139] <0.01
MAP minimum, mmHg 56 [48–64] 52 [43–62] <0.01
Temperature maximum (°C) 37.8 [37.3–38.5] 37.9 [37.4–38.5] 0.6
Selected laboratory results
WBC max k/μL 13.3 [9.4–18.3] 14.6 [10.2–20.5] <0.01
Lactate max mMol/L 2.1 [1.4–3.7] 2.6 [1.6–4.8] <0.01
Creat max mg/dL 1.1 [0.8–1.8] 1.2 [0.8–2.0] 0.04
Treatments received
Renal replacement 288 (11 %) 50 (15 %) 0.04
Vasopressor use 741 (29 %) 125 (39 %) <0.01
Mechanical ventilation 1298 (51 %) 198 (61 %) <0.01
IV fluids, L (first 24 h) 2.2 [0.6–5.2] 2.5 [0.7–5.7] 0.2
HDLVEF hyperdynamic left ventricular ejection fraction on echocardiogram, IV intravenous, MAP mean arterial pressure, NLVEF normal left ventricular ejection
fraction on echocardiogram, SOFA Sequential Organ Failure Assessment, WBC white blood cell count
Acute illness severity and treatments performed for patients with NLVEF compared with HDLVEF are displayed as either n (%) or median [IQR]. p Values <0.01 are
listed in bold
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understood. Cardiac function is extremely variable in the
setting of critical illness and depends on multiple physio-
logic determinants [3]. Cardiac systolic function is re-
lated to heart rate, preload, afterload, and contractility.
A patient’s EF may be hyperdynamic in the setting of
critical illness owing to changes in these basic physio-
logic parameters.
Prior research suggested that hypovolemia could lead
to HDLVEF [14]. In contrast, a small study showed that
three of four patients with HDLVEF on transesophageal
echocardiography had pulmonary capillary wedge pres-
sures >20 mmHg, which argues against hypovolemia as
an etiology [15]. In our study, patients with NLVEF and
HDLVEF received a similar amount of intravenous fluidTable 3 Multivariable logistic regression model for 28-day
mortality
Odds ratio (95 % confidence interval) p value
Age 1.011 (1.007–1.016) <0.001
Male sex 0.972 (0.792–1.192) 0.8
Elixhauser score 1.054 (1.037–1.071) <0.001
SOFA score 1.128 (1.091–1.166) <0.001
Mechanical ventilation 1.177 (0.906–1.530) 0.2
Vasopressor use 1.210 (0.943–1.549) 0.1
HDLVEF 1.389 (1.039–1.842) 0.02
HDLVEF hyperdynamic left ventricular ejection fraction on echocardiogram,
SOFA Sequential Organ Failure Assessment
Multivariable logistic regression model for 28-day mortality in all patients.
p Values <0.05 are listed in boldin the first 24 h (Table 1), although this cannot exclude
hypovolemia and decreased systemic vascular resistance
as contributors to HDLVEF.
HDLVEF was also found to be associated with cancer.
Many studies have shown increased cytokine levels in
patients with various types of cancer [16–19], which
may explain the presence of HDLVEF among critically ill
patients with cancer.
It is unclear if diastolic dysfunction contributes to the
development of HDLVEF. It is plausible that patients
with diastolic dysfunction are more likely to develop
HDLVEF, either chronically or in the setting of acute ill-
ness, to compensate for the reduced preload from im-
paired relaxation during ventricular filling. Another
mechanism could be increased circulating cytokines
within the tumor necrosis factor α axis, which has been
suggested to be a contributor to the development of
CHF with preserved EF [20]. Several other biomarkers of
myocyte stress, inflammation, and extracellular matrix
remodeling have been shown to be associated with CHF
with preserved EF [21]. It is unknown if this may be seen
in HDLVEF as well. Alternatively, mismatch of myocar-
dial contractility and arterial compliance may be present
in patients with HDLVEF, which might explain the trend
toward development of CHF. The presence of ventricu-
loarterial decoupling, defined as the ratio of the arterial
elastance to the ventricular elastance, can be found in
many disease states and may lead to worse outcomes
[22]. These inferences cannot be deduced from our ana-
lysis and should be investigated further.
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that HDLVEF is more frequently seen with a diagnosis
of sepsis. Adequately resuscitated patients with severe
sepsis can have warm peripheries, high cardiac output,
and HDLVEF [23]. Despite a prior study suggesting that
HDLVEF was highly specific for sepsis, our study
showed that HDLVEF was seen frequently outside the
diagnosis of sepsis. It is also important to note that EF
may be depressed in sepsis, as has been demonstrated in
prior studies [19, 24–28]. The information in the litera-
ture is mixed with regard to EF and prognosis in patients
with sepsis [29, 30]. In addition to systolic dysfunction,
diastolic dysfunction has been described in sepsis [26,
27]. It might contribute to the development of HDLVEF,
though this present study was not designed for such an
investigation.
Limitations
Our study is limited by its retrospective nature and its
inclusion of a relatively heterogeneous group of patients
whose data were extracted from electronic medical re-
cords in a large clinical database. Other variables not
captured in the database may account for residual con-
founding. Disease associations such as hypertension and
cancer are based on ICD-9 codes, which can lead to in-
consistent levels of reporting, but this may be somewhat
mitigated by the single-center scope of the study. The
indications for TTE could be variable and could not be
accounted for in this study. Common reasons for TTE
in our institution include workup for hypotension and
heart failure and evaluation for bacterial endocarditis or
right heart strain owing to acute pulmonary embolism.
In this study, the need for TTE was at the discretion of
the ordering physicians. The indication was not
documented.
Bias might have been introduced by excluding patients
without TTE during their ICU admission. We compared
patients who had TTE to those without TTE with respect
to the parameters listed in Table 1, in addition to mortality
data. On the basis of this additional analysis, we found
that the patients who did not undergo TTE were younger,
had fewer comorbidities, were less sick (based on SOFA
scores, vital signs, laboratory results, use of vasopressors,
and mechanical ventilation), and had better outcomes
(data not shown) than other patients. This makes sense
from a clinical standpoint—the physicians did not feel that
additional information provided by TTE was necessary to
manage these patients. These patients who were excluded
because they did not undergo TTE look more similar to
those patients with NLVEF than to those with HDLVEF. If
most of the excluded patients indeed had NLVEF, their in-
clusion into the analysis, assuming that they had NLVEF,
would likely have increased the effect size, given their bet-
ter outcomes.Implications
To our knowledge, this study is the first large-scale
evaluation of HDLVEF in the ICU setting. It is difficult
to determine exactly why HDLVEF has a worse progno-
sis when seen during critical illness. The etiology of in-
creased mortality in the HDLVEF group may be related
to the myocardial mechanics of HDLVEF, or it could be
a marker or proxy of a pathophysiologic process. The
presence of HDLVEF, in addition to traditional mortality
risk predictors, may provide additional prognostic impli-
cations for ICU patients.
Further research
HDLVEF patients may respond differently to common
interventions such as fluid administration, vasopressor
use, and mechanical ventilation. If cardiovascular me-
chanics are the etiology of worse prognosis, then further
studies might be considered to investigate whether
modulating HDLVEF with pharmacotherapy improves
outcomes. Interestingly, β-blockade has been shown to
decrease mortality in patients with severe septic shock
[31]. If catecholamine surge is the etiology of HDLVEF,
closely monitored β-blockade might be examined to at-
tenuate the HDLVEF. Similarly, the trend toward associ-
ation between CHF and HDLVEF is interesting and
warrants further investigation.
Conclusions
Compared with critically ill patients with NLVEF, the find-
ing of HDLVEF in critically ill patients was associated with
female sex, increased age, and diagnoses of hypertension
and cancer. Patients with HDLVEF had increased 28-day
mortality compared with those with normal EF in multi-
variate logistic regression analysis adjusting for age, sex,
SOFA score, Elixhauser score of comorbidities, vasopres-
sor use, and mechanical ventilation use. The presence of
HDLVEF portended increased 28-day mortality and may
be helpful as a gravity marker for prognosis of patients ad-
mitted to the ICU. Further research is warranted to better
understand how these patients respond to common inter-
ventions in the ICU and to determine if pharmacologic
modulation of HDLVEF improves outcomes.
Key messages
 HDLVEF prevalence was 8.6 % in ICU patients who
underwent TTE during their ICU admission.
 HDLVEF in the ICU has not been well described in
the literature, especially on a large scale.
 The finding of HDLVEF was associated with female
sex, increased age, hypertension, and cancer.
 Patients with HDLVEF were sicker and had
increased adjusted 28-day mortality compared with
the other patients.
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how HDLVEF patients respond to common
interventions in the ICU.
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